At Long Last, FDA Unveils Plan for Rare Disease Innovation Hub
FDA Law Blog
JULY 17, 2024
Importantly, the Hub is intended to establish a new model within FDA, which leverages cross-Agency expertise in providing guidance and conducting reviews for products for rare disease populations. clinical pharmacology/biomarkers, animal models, real-world evidence and other externally controlled comparisons [e.g.,
Let's personalize your content